MedTrace Logo

Efficacy and Safety of Liposomal Bupivacaine Injection for Paravertebral Nerve Block in the Treatment of Acute and Chronic Pain After Thoracoscopic Pneumonectomy: A Multicenter, Randomized, Double-blind, Controlled Clinical Trial

NCT06569953 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 284

Last updated 2025-06-27

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of liposomal Bupivacaine administered by paravertebral block for the treatment of acute and chronic pain after video-assisted thoracoscopic lobectomy.

Conditions

Interventions

DRUG

Liposomal bupivacaine

Participants randomized to the intervention arm received 266 mg of liposomal bupivacaine for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline).

DRUG

Bupivacaine Hydrochloride

Participants randomized to the intervention arm received 0.5% 100 mg of bupivacaine hydrochloride for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline)

Sponsors & Collaborators

  • People's Hospital of Chongqing

    collaborator OTHER

  • LanZhou University

    collaborator OTHER

  • Xiangya Hospital of Central South University

    collaborator OTHER

  • Shapingba District People's Hospital of Chongqing

    collaborator UNKNOWN

  • The Second Affiliated Hospital of Chongqing Medical University

    lead OTHER

Principal Investigators

  • He Huang, ph.D · The Second Affiliated Hospital of Chongqing Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-26
Primary Completion
2025-08-31
Completion
2025-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06569953 on ClinicalTrials.gov